Symbols / IGC $0.27 -2.32% IGC Pharma, Inc.
IGC Chart
About
IGC Pharma, Inc., a clinical stage pharmaceutical company, develops novel therapeutic candidates for neuropsychiatric and neurodegenerative disorders, with a primary focus on Alzheimer's disease in the United States and Colombia. The company's lead product is IGC-AD1 that is in Phase II clinical trial for the treatment of agitation in dementia due to Alzheimer's. Its pre-clinical stage product candidate includes TGR-63 and IGC-M3 to treat Alzheimer's disease. In addition, the company develops MINT-AD, an AI-driven assistant for healthcare providers. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. IGC Pharma, Inc. was incorporated in 2005 and is headquartered in Potomac, Maryland.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 26.19M |
| Enterprise Value | 23.64M | Income | -6.45M | Sales | 1.11M |
| Book/sh | 0.09 | Cash/sh | 0.01 | Dividend Yield | — |
| Payout | 0.00% | Employees | 70 | IPO | — |
| P/E | — | Forward P/E | -2.95 | PEG | — |
| P/S | 23.68 | P/B | 3.01 | P/C | — |
| EV/EBITDA | -3.14 | EV/Sales | 21.37 | Quick Ratio | 0.79 |
| Current Ratio | 1.32 | Debt/Eq | 1.80 | LT Debt/Eq | — |
| EPS (ttm) | -0.06 | EPS next Y | -0.09 | EPS Growth | — |
| Revenue Growth | -53.60% | Earnings | 2025-11-14 16:00 | ROA | -50.31% |
| ROE | -83.34% | ROIC | — | Gross Margin | 46.20% |
| Oper. Margin | -15.18% | Profit Margin | 0.00% | Shs Outstand | 98.80M |
| Shs Float | 84.64M | Short Float | 1.20% | Short Ratio | 2.20 |
| Short Interest | — | 52W High | 0.50 | 52W Low | 0.24 |
| Beta | 0.31 | Avg Volume | 358.71K | Volume | 84.78K |
| Target Price | $4.00 | Recom | None | Prev Close | $0.27 |
| Price | $0.27 | Change | -2.32% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$4.00
Mean price target
2. Current target
$0.27
Latest analyst target
3. DCF / Fair value
$-0.46
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.27
Low
$3.00
High
$5.00
Mean
$4.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-23 | main | Ascendiant Capital | Buy → Buy | $5 |
| 2025-12-09 | main | Ascendiant Capital | Buy → Buy | $5 |
| 2025-08-26 | main | Ascendiant Capital | Buy → Buy | $5 |
| 2025-03-06 | reit | Alliance Global Partners | Buy → Buy | $4 |
| 2025-02-24 | main | Ascendiant Capital | Buy → Buy | $4 |
| 2024-12-05 | main | Ascendiant Capital | Buy → Buy | $4 |
| 2024-09-03 | main | Ascendiant Capital | Buy → Buy | $4 |
| 2024-07-29 | main | Ascendiant Capital | Buy → Buy | $4 |
| 2024-07-17 | init | Alliance Global Partners | — → Buy | $4 |
| 2024-06-21 | reit | Ascendiant Capital | Buy → Buy | $3 |
News
RSS: Latest IGC news- IGC Stock Price, Quote & Chart | IGC PHARMA INC (NYSEARCA:IGC) - chartmill.com hu, 02 Apr 2026 07
- IGC's Alzheimer's drug trial passes 70% enrollment as loss narrows - Stock Titan hu, 19 Mar 2026 07
- Would You Still Hold IGC Pharma Stock If It Fell Another 30%? - trefis.com Sat, 20 Dec 2025 08
- IGC Stock: Ascendiant Capital Maintains Buy Rating, Raises Price - GuruFocus Mon, 23 Feb 2026 08
- IGC Pharma, Inc. (IGC) Reports Q2 Loss, Misses Revenue Estimates - finance.yahoo.com Fri, 14 Nov 2025 08
- IGC Pharma Launches National Media Partnership to Boost Visibility - TipRanks ue, 31 Mar 2026 00
- IGC Pharma (IGC) price target increased by 10.34% to 4.08 - MSN Wed, 01 Apr 2026 19
- IGC Pharma heads to Fox Business, Bloomberg in 12-part TV push - Stock Titan Mon, 30 Mar 2026 12
- New Strong Buy Stocks for Oct. 24: IGC, ASM and More - finance.yahoo.com Fri, 24 Oct 2025 07
- IGC.WS (India Globalization Capital) PB Ratio : (As of Apr. 03, 2026) - GuruFocus Sat, 04 Apr 2026 01
- Analyst lifts IGC Pharma price target to $5 in new research note - Stock Titan ue, 24 Feb 2026 08
- All You Need to Know About IGC Pharma, Inc. (IGC) Rating Upgrade to Strong Buy - finance.yahoo.com Fri, 24 Oct 2025 07
- Alzheimer’s agitation trial passes 70% enrollment milestone - Stock Titan Mon, 02 Feb 2026 08
- IGC Pharma (NYSE: IGC) inks 12-part New to The Street deal - Stock Titan Mon, 30 Mar 2026 21
- Colombia’s unique inherited Alzheimer’s community joins IGC drug trial - Stock Titan Mon, 09 Feb 2026 08
Insider Transactions
Financials
Statement View
| Line Item | Trend | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
1.27
-5.50%
|
1.34
+47.64%
|
0.91
+129.47%
|
0.40
|
| Operating Revenue |
|
1.27
+7.62%
|
1.18
+29.64%
|
0.91
+129.47%
|
0.40
|
| Cost Of Revenue |
|
0.65
+6.54%
|
0.61
+30.49%
|
0.47
+131.03%
|
0.20
|
| Reconciled Cost Of Revenue |
|
0.65
+6.54%
|
0.61
+30.49%
|
0.47
+131.03%
|
0.20
|
| Gross Profit |
|
0.62
-15.55%
|
0.73
+65.84%
|
0.44
+127.84%
|
0.19
|
| Operating Expense |
|
8.06
-23.42%
|
10.53
-12.34%
|
12.01
-23.10%
|
15.62
|
| Research And Development |
|
3.65
-3.13%
|
3.77
+9.01%
|
3.46
+48.54%
|
2.33
|
| Selling General And Administration |
|
4.41
-34.74%
|
6.76
-20.98%
|
8.55
-35.66%
|
13.29
|
| Total Expenses |
|
8.72
-21.77%
|
11.14
-10.73%
|
12.48
-21.12%
|
15.82
|
| Operating Income |
|
-7.45
+24.00%
|
-9.80
+15.32%
|
-11.57
+25.00%
|
-15.43
|
| Total Operating Income As Reported |
|
-7.45
+24.00%
|
-9.80
+15.32%
|
-11.57
+25.00%
|
-15.43
|
| EBITDA |
|
-6.98
+23.79%
|
-9.16
+16.06%
|
-10.91
+26.14%
|
-14.78
|
| Normalized EBITDA |
|
-6.98
-20.05%
|
-5.82
+46.71%
|
-10.91
+25.90%
|
-14.73
|
| Reconciled Depreciation |
|
0.46
-27.16%
|
0.64
-3.04%
|
0.66
+0.92%
|
0.65
|
| EBIT |
|
-7.45
+24.00%
|
-9.80
+15.32%
|
-11.57
+25.00%
|
-15.43
|
| Total Unusual Items |
|
0.00
+100.00%
|
-3.35
|
0.00
+100.00%
|
-0.05
|
| Total Unusual Items Excluding Goodwill |
|
0.00
+100.00%
|
-3.35
|
0.00
+100.00%
|
-0.05
|
| Special Income Charges |
|
0.00
+100.00%
|
-3.35
|
0.00
+100.00%
|
-0.05
|
| Impairment Of Capital Assets |
|
0.00
-100.00%
|
3.35
|
0.00
|
—
|
| Write Off |
|
—
|
—
|
0.00
-100.00%
|
0.05
|
| Net Income |
|
-7.12
+45.22%
|
-13.00
-12.98%
|
-11.51
+23.38%
|
-15.02
|
| Pretax Income |
|
-7.12
+45.22%
|
-13.00
-12.98%
|
-11.51
+23.38%
|
-15.02
|
| Other Income Expense |
|
0.33
+110.15%
|
-3.20
-5026.15%
|
0.07
-84.22%
|
0.41
|
| Other Non Operating Income Expenses |
|
0.33
+127.27%
|
0.14
+120.00%
|
0.07
-85.90%
|
0.46
|
| Tax Provision |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-7.12
+45.22%
|
-13.00
-12.98%
|
-11.51
+23.38%
|
-15.02
|
| Net Income From Continuing Operation Net Minority Interest |
|
-7.12
+45.22%
|
-13.00
-12.98%
|
-11.51
+23.38%
|
-15.02
|
| Net Income From Continuing And Discontinued Operation |
|
-7.12
+45.22%
|
-13.00
-12.98%
|
-11.51
+23.38%
|
-15.02
|
| Net Income Continuous Operations |
|
-7.12
+45.22%
|
-13.00
-12.98%
|
-11.51
+23.38%
|
-15.02
|
| Normalized Income |
|
-7.12
+26.25%
|
-9.65
+16.09%
|
-11.51
+23.12%
|
-14.97
|
| Net Income Common Stockholders |
|
-7.12
+45.22%
|
-13.00
-12.98%
|
-11.51
+23.38%
|
-15.02
|
| Diluted EPS |
|
-0.09
+59.09%
|
-0.22
+0.00%
|
-0.22
+26.67%
|
-0.30
|
| Basic EPS |
|
-0.09
+59.09%
|
-0.22
+0.00%
|
-0.22
+26.67%
|
-0.30
|
| Basic Average Shares |
|
76.52
+30.04%
|
58.84
+11.91%
|
52.58
+5.17%
|
49.99
|
| Diluted Average Shares |
|
76.52
+30.04%
|
58.84
+11.91%
|
52.58
+5.17%
|
49.99
|
| Diluted NI Availto Com Stockholders |
|
-7.12
+45.22%
|
-13.00
-12.98%
|
-11.51
+23.38%
|
-15.02
|
| Line Item | Trend | 2024-03-31 |
|---|---|---|
| Total Assets |
|
9.90
|
| Current Assets |
|
3.71
|
| Cash Cash Equivalents And Short Term Investments |
|
1.20
|
| Cash And Cash Equivalents |
|
1.20
|
| Cash Equivalents |
|
0.29
|
| Cash Financial |
|
0.91
|
| Other Short Term Investments |
|
0.00
|
| Receivables |
|
0.09
|
| Accounts Receivable |
|
0.04
|
| Gross Accounts Receivable |
|
0.06
|
| Allowance For Doubtful Accounts Receivable |
|
-0.02
|
| Other Receivables |
|
0.05
|
| Inventory |
|
1.54
|
| Raw Materials |
|
1.10
|
| Work In Process |
|
0.00
|
| Finished Goods |
|
0.44
|
| Prepaid Assets |
|
0.04
|
| Assets Held For Sale Current |
|
0.72
|
| Other Current Assets |
|
0.12
|
| Total Non Current Assets |
|
6.20
|
| Net PPE |
|
3.89
|
| Gross PPE |
|
6.33
|
| Accumulated Depreciation |
|
-2.44
|
| Properties |
|
0.00
|
| Land And Improvements |
|
0.00
|
| Buildings And Improvements |
|
2.30
|
| Machinery Furniture Equipment |
|
3.83
|
| Construction In Progress |
|
0.00
|
| Other Properties |
|
0.20
|
| Goodwill And Other Intangible Assets |
|
1.62
|
| Other Intangible Assets |
|
1.62
|
| Investments And Advances |
|
—
|
| Other Investments |
|
—
|
| Non Current Accounts Receivable |
|
0.69
|
| Non Current Prepaid Assets |
|
0.00
|
| Total Liabilities Net Minority Interest |
|
2.58
|
| Current Liabilities |
|
2.34
|
| Payables And Accrued Expenses |
|
0.77
|
| Payables |
|
0.77
|
| Accounts Payable |
|
0.77
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
0.82
|
| Current Debt And Capital Lease Obligation |
|
0.12
|
| Current Debt |
|
—
|
| Other Current Borrowings |
|
—
|
| Current Capital Lease Obligation |
|
0.12
|
| Other Current Liabilities |
|
0.42
|
| Total Non Current Liabilities Net Minority Interest |
|
0.24
|
| Long Term Debt And Capital Lease Obligation |
|
0.22
|
| Long Term Debt |
|
0.14
|
| Long Term Capital Lease Obligation |
|
0.08
|
| Long Term Provisions |
|
0.02
|
| Other Non Current Liabilities |
|
—
|
| Stockholders Equity |
|
7.32
|
| Common Stock Equity |
|
7.32
|
| Capital Stock |
|
124.41
|
| Common Stock |
|
124.41
|
| Share Issued |
|
66.69
|
| Ordinary Shares Number |
|
66.69
|
| Treasury Shares Number |
|
0.00
|
| Retained Earnings |
|
-113.67
|
| Gains Losses Not Affecting Retained Earnings |
|
-3.42
|
| Other Equity Adjustments |
|
-3.42
|
| Total Equity Gross Minority Interest |
|
7.32
|
| Total Capitalization |
|
7.46
|
| Working Capital |
|
1.36
|
| Invested Capital |
|
7.46
|
| Total Debt |
|
0.34
|
| Capital Lease Obligations |
|
0.21
|
| Net Tangible Assets |
|
5.71
|
| Tangible Book Value |
|
5.71
|
| Current Provisions |
|
0.21
|
| Line Item | Trend | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-4.07
+21.81%
|
-5.20
+26.22%
|
-7.05
+5.56%
|
-7.46
|
| Cash Flow From Continuing Operating Activities |
|
-4.07
+21.81%
|
-5.20
+26.22%
|
-7.05
+5.56%
|
-7.46
|
| Net Income From Continuing Operations |
|
-5.92
+54.43%
|
-13.00
-12.98%
|
-11.51
+23.38%
|
-15.02
|
| Depreciation Amortization Depletion |
|
0.46
-27.16%
|
0.64
-3.04%
|
0.66
+0.92%
|
0.65
|
| Depreciation |
|
—
|
0.56
|
—
|
—
|
| Amortization Cash Flow |
|
—
|
0.07
|
—
|
—
|
| Depreciation And Amortization |
|
0.46
-27.16%
|
0.64
-3.04%
|
0.66
+0.92%
|
0.65
|
| Amortization Of Intangibles |
|
—
|
0.07
|
—
|
—
|
| Other Non Cash Items |
|
—
|
—
|
—
|
-0.43
|
| Stock Based Compensation |
|
1.19
-33.16%
|
1.77
-37.64%
|
2.84
+29.40%
|
2.20
|
| Provisionand Write Offof Assets |
|
0.00
-100.00%
|
0.09
-26.19%
|
0.13
-92.67%
|
1.72
|
| Asset Impairment Charge |
|
0.00
-100.00%
|
3.45
|
0.00
-100.00%
|
0.88
|
| Operating Gains Losses |
|
-0.01
+68.18%
|
-0.04
-212.82%
|
0.04
+109.07%
|
-0.43
|
| Gain Loss On Sale Of PPE |
|
-0.03
+43.18%
|
-0.04
-212.82%
|
0.04
|
0.00
|
| Change In Working Capital |
|
0.22
-88.17%
|
1.89
+138.54%
|
0.79
-68.69%
|
2.54
|
| Change In Receivables |
|
-0.01
+60.00%
|
-0.03
-600.00%
|
0.01
-90.00%
|
0.05
|
| Changes In Account Receivables |
|
-0.01
+60.00%
|
-0.03
-600.00%
|
0.01
-90.00%
|
0.05
|
| Change In Inventory |
|
0.11
-89.38%
|
1.01
+12.37%
|
0.90
-53.52%
|
1.93
|
| Change In Prepaid Assets |
|
-0.19
-226.67%
|
0.15
-74.62%
|
0.59
+9.24%
|
0.54
|
| Change In Payables And Accrued Expense |
|
0.31
-28.86%
|
0.44
+181.63%
|
-0.54
-243.73%
|
0.38
|
| Change In Accrued Expense |
|
0.25
+27.41%
|
0.20
+323.86%
|
-0.09
+31.78%
|
-0.13
|
| Change In Payable |
|
0.06
-74.49%
|
0.24
+153.88%
|
-0.45
-189.48%
|
0.50
|
| Change In Account Payable |
|
0.06
-74.49%
|
0.24
+153.88%
|
-0.45
-189.48%
|
0.50
|
| Change In Other Current Assets |
|
0.08
-82.88%
|
0.44
+1807.69%
|
-0.03
+91.22%
|
-0.30
|
| Change In Other Current Liabilities |
|
-0.07
+41.46%
|
-0.12
+8.21%
|
-0.13
-109.38%
|
-0.06
|
| Investing Cash Flow |
|
-0.30
+5.36%
|
-0.32
-34.89%
|
-0.23
+68.33%
|
-0.74
|
| Cash Flow From Continuing Investing Activities |
|
-0.30
+5.36%
|
-0.32
-34.89%
|
-0.23
+68.33%
|
-0.74
|
| Net PPE Purchase And Sale |
|
-0.08
+17.02%
|
-0.09
-141.23%
|
0.23
+210.14%
|
-0.21
|
| Purchase Of PPE |
|
-0.09
+31.88%
|
-0.14
+55.48%
|
-0.31
-31.36%
|
-0.24
|
| Sale Of PPE |
|
0.02
-63.64%
|
0.04
-91.82%
|
0.54
+1755.17%
|
0.03
|
| Capital Expenditure |
|
-0.32
+38.64%
|
-0.52
+16.80%
|
-0.62
+19.71%
|
-0.77
|
| Net Investment Purchase And Sale |
|
0.00
-100.00%
|
0.15
+200.00%
|
-0.15
|
0.00
|
| Purchase Of Investment |
|
0.00
|
—
|
-0.15
|
0.00
|
| Sale Of Investment |
|
—
|
—
|
—
|
0.00
|
| Net Intangibles Purchase And Sale |
|
-0.22
+41.11%
|
-0.38
-22.01%
|
-0.31
+42.24%
|
-0.54
|
| Purchase Of Intangibles |
|
-0.22
+41.11%
|
-0.38
-22.01%
|
-0.31
+42.24%
|
-0.54
|
| Financing Cash Flow |
|
3.65
+3.46%
|
3.52
+3424.00%
|
0.10
-97.59%
|
4.14
|
| Cash Flow From Continuing Financing Activities |
|
3.65
+3.46%
|
3.52
+3424.00%
|
0.10
-97.59%
|
4.14
|
| Net Issuance Payments Of Debt |
|
-0.00
+0.00%
|
-0.00
+0.00%
|
-0.00
+0.00%
|
-0.00
|
| Repayment Of Debt |
|
-0.00
+0.00%
|
-0.00
+0.00%
|
-0.00
+0.00%
|
-0.00
|
| Long Term Debt Payments |
|
-0.00
+0.00%
|
-0.00
+0.00%
|
-0.00
+0.00%
|
-0.00
|
| Net Long Term Debt Issuance |
|
-0.00
+0.00%
|
-0.00
+0.00%
|
-0.00
+0.00%
|
-0.00
|
| Net Common Stock Issuance |
|
3.65
+3.46%
|
3.53
+3324.27%
|
0.10
-97.52%
|
4.14
|
| Changes In Cash |
|
-0.72
+63.91%
|
-1.99
+72.26%
|
-7.18
-76.81%
|
-4.06
|
| Effect Of Exchange Rate Changes |
|
-0.01
-50.00%
|
-0.01
+92.68%
|
-0.08
-215.38%
|
-0.03
|
| Beginning Cash Position |
|
1.20
-62.52%
|
3.20
-69.45%
|
10.46
-28.10%
|
14.55
|
| End Cash Position |
|
0.47
-60.77%
|
1.20
-62.52%
|
3.20
-69.45%
|
10.46
|
| Free Cash Flow |
|
-4.38
+23.33%
|
-5.71
+25.46%
|
-7.67
+6.89%
|
-8.23
|
| Interest Paid Supplemental Data |
|
—
|
—
|
—
|
0.00
|
| Common Stock Issuance |
|
3.65
+3.46%
|
3.53
+3324.27%
|
0.10
-97.52%
|
4.14
|
| Issuance Of Capital Stock |
|
3.65
+3.46%
|
3.53
+3324.27%
|
0.10
-97.52%
|
4.14
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 8-K2026-03-30 View
- 8-K2026-03-12 View
- 42026-02-04 View
- 42026-01-20 View
- 8-K2026-01-06 View
- 8-K2026-01-02 View
- 8-K2025-12-15 View
- 10-Q2025-11-14 View
- 8-K2025-11-14 View
- 42025-10-22 View
- 42025-10-21 View
- 42025-10-21 View
- 42025-10-21 View
- 42025-10-20 View
- 8-K2025-10-14 View
- 8-K2025-10-01 View
- 10-Q2025-08-14 View
- 10-K2025-06-27 View
- 8-K2025-06-17 View
- 10-Q2025-02-14 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|